PRKAB1 and metabolic dysfunction-associated steatohepatitis: Indeed, AMPK activity is reduced in NAFLD and NASH, and liver-specific AMPK reduction leads to NASH phenotypes such as fibrosis and cell death (Li et al., 2020; Fang et al., 2022).